Highlighted Article Flyer for the journal “Recent Patents on Mechanical Engineering”

RPME-Articles_9-2- Jiang jingang


Editor’s Pick

ISSN: 1874-7647 (Online)
ISSN: 2211-3320 (Print)
Volume 7, 2 Issues, 2014

Innovations to Control the Environment for Persons with Movement Disorders: Support in Home Care

Author(s): Maria Linden and Anna Akerberg 
Pages 109-126 (18)


 This review focuses on recent innovations and patents with the aim to allow people with movement disorders to control their environment. This particularly includes different technologies for input devices to control computers and other electronic equipment used by persons with movement disorders, enabling the empowerment of this user group. The control of such devices can be the key to social inclusion and mean improved social contact with others, access of information or possibility to work. In this paper, several patents and innovations are described that enable such control, divided into the groups; Input devices in form of switches and touchscreens, Inertia and inclinometer sensors, Voice control and Gesture control. Also methods allowing monitoring and classification of physical activity, i.e. assisting to alarm in case of a fall and systems assisting in rehabilitation at home, are included, as are video games aimed to promote physical activity.

For details, please click on: http://benthamscience.com/journal/index.php?journalID=rpbiomeng#topImage

Chemical Abstracts Service (CAS) indexes Current Green Chemistry

Chemical Abstracts Service (CAS) indexes Current Green Chemistry

Chemical Abstracts Service, a division of the American Chemical Society accepts to index in CAS a new journal Current Green Chemistry published by Bentham Science Publishers.

Current Green Chemistry is an international peer-reviewed journal that publishes original research, expert reviews and thematic issues in all major areas of green chemistry. For further details and FREE first issue viewing visit the journal’s website at Current Green Chemistry

Chemical Abstracts Service (CAS) aims to deliver comprehensive and useful digital information environment for scientific research and discovery.

The Awaited podcast by Dr. Kunihiro Suzuki is here!

Ebook: “Ion Implantation and Activation”.

Anatomically Correct Version of Skeleton!

Anatomically Correct Version of Skeleton!

The artist Aaron Keuhn has identified all the bones of the human body and arranged them in an anatomically correct skeleton.

Gene therapy partially restores vision in rare blindness disorder

Two men with progressive blindness have regained some of their vision after taking part in the first clinical trial of a gene therapy for the condition.

The men were among six patients to have experimental treatment for a rare, inherited, disorder called choroideremia, which steadily destroys eyesight and leaves people blind in middle age.

After therapy to correct a faulty gene, the men could read two to four more lines on an optician’s sight chart, a dramatic improvement that has held since the doctors treated them. One man was treated more than two years ago.

The other four patients, who had less advanced disease and good eyesight before the trial, had better night vision after the therapy. Poor sight in dim light is one of the first signs of the condition.

Writing in The Lancet , doctors describe the progress of the patients six months after the therapy. If further trials are as effective, the team could apply for approval for the therapy in the next five years. Some other forms of blindness could be treated in a similar way.

Toby Stroh, 56, a solicitor from London, was in his early 20s when a consultant told him he would be blind by the age of 50. “I said ‘what do you mean?’ and he said, ‘you won’t be able to see me’. It was a long way away, but still a bit of a shock.”

Stroh was told later that his vision had deteriorated so much he would have to stop driving. Then, when he joined a solicitors’ firm he told a partner his eyesight was not expected to last. The response was: “We’ll be sorry to see you go.”

Stroh had gene therapy to his left eye, the worst eye, in February 2012, and has had some sight return to it.

“This result does not make me swing from the chandeliers. I refuse to say everything is going to be roses. But there is hope,” he said. “For the past 30 years I’ve been living under the awfulness, the insidious inevitability, of going blind, and now as a result of this work that’s been done there is a very real prospect that I will continue to be able to see, and that is just absolutely fantastic.”

Jonathan Wyatt, 65, a barrister from Bristol, was the first patient to have the therapy. He had hoped to spend his youth surfing around the world, but changed his mind at the age of 20 when a consultant told him he had no idea if his vision would last one, two or three more years.

Wyatt had gene therapy in October 2011 and soon after was able to read the numbers on a mobile phone for the first time in five years. “In my view my eyesight has improved enormously since the operation.”

Doctors said the improvements in the two patients went far beyond their expectations, but they cautioned that it was too soon to say whether the effects would last.

“It is still too early to know if the treatment we have initiated is a permanent cure, but so far the vision that we’ve seen improved has been maintained,” said Robert MacLaren, a consultant surgeon at the Oxford Eye Hospital, who led the trial.

Choroideremia is an X-linked disorder, meaning it is caused by a faulty gene, called CHM, on the X chromosome. The disease mostly affects men because they have only one copy of the X chromosome. Women have two copies of the X chromosome, so a healthy version of the gene on one chromosome can largely make up for any defects on the other.

The therapy uses a genetically modified virus to smuggle healthy copies of the CHM gene into light-sensitive cells in the retina and supporting tissue called retinal pigment epithelium.

Surgeons injected 10bn modified virus particles behind the retinas of the first six patients in an operation that could be completed in an hour under general anaesthetic.

The injected viruses infect the eye cells, which then use the new CHM gene to correct the choroideremia. The therapy only works on cells that have not been destroyed by the disease. It cannot replace cells that have died off.

MacLaren has given three more patients a higher dose of the gene therapy and hopes to start a larger trial with about 30 people next year.

Wayne Thompson, 43, an IT manager in Staffordshire, was treated in April 2013. His night vision began to fail in his 20s, and over time his peripheral vision got worse, until he began to use a white cane to get around.

“One night in the summer my wife called me outside as it was a particularly starry evening. As I looked up I was amazed that I was able to see a few stars. I hadn’t seen stars for a long, long, time,” Thompson said. “Even if the improvement lasts I will still be visually impaired. My life has not become easier because of the trial, but it may have stopped it getting much, much, harder.”

The work raises hopes for gene therapies for more common causes of blindness, such as retinitis pigmentosa and age-related macular degeneration. Some forms of blindness cause rapid sight loss, and are caused by multiple genes, so therapy might need to be given in childhood and correct several genes at once.

“It’s pretty convincing that they see some functional improvement in the treated eyes,” said Hendrik Scholl, professor of ophthalmology at Johns Hopkins University. “I find this very exciting.”

But he added that measurements of supporting tissues, called retinal pigment epithelial cells, seemed to show that the therapy had not stopped the degeneration of the eye completely. “The data suggest that they were able to slow down the progression of the disease, but not stop it. But after only six months it is very difficult to draw any conclusions.”

[Source: theguardian.com]

Happy 82nd Birthday to an amazing Zoologist!


Dian Fossey was born on January 16, 1932, in San Francisco, California. While working as an occupational therapist, Fossey became interested in primates during a trip to Africa in 1963. She studied the endangered gorillas of the Rwandan mountain forest for two decades before her unsolved murder occurred in 1985, at Volcanoes National Park in Rwanda. Fossey told her story in the book Gorillas in the Mist (1983).

Good bacterium’ prevents colic symptoms in newborns

Newborns who take drops containing a beneficial bacterium cry less than babies not given the supplement, researchers report January 13 inJAMA Pediatrics.


The cause of excessive crying — or colic – is not well understood, but scientists suspect that the microbial mix in infants’ intestines is involved.  Researchers at the University of Bari Aldo Moro in Italy teamed with other scientists across Italy to randomly assign 589 newborns to get either a placebo or a probiotic supplement. The supplement contained live Lactobacillus reuteri, a microbe shown previously to improve intestinal function. Parents delivered the drops and kept detailed diaries of infant health for three months.

Newborns getting the microbe were less apt to develop colic symptoms. They cried for an average of 38 minutes per day; infants getting placebo cried for 71 minutes. The microbe-treated babies also spit up less often. These improvements meant fewer doctor visits and trips to emergency departments for the infants. Parents whose babies got the microbes lost only about half a day of work during the study, compared with nearly three days for parents of infants getting a placebo.

[Source: sciencenews.org]

Appreciation For One of the Managers of Bentham Science Publishers From a Guest Editor

Bentham Science Publishers applaud Ms. Shabana Seemee for her unfaltering devotion to the journal “Novel Agents in the Treatment of Osteoporosis and its Complications.

One of the Guest Editors, not only held Bentham Science Publishers in the highlight but also appreciated the efforts of Ms. Shabana Seemee.


Happy Birthday!!

Happy Birthday!!

Birthday Wishes for Prof. Christopher Tyler from the Bentham Science Family.

%d bloggers like this: